1. Kurokawa I, Danby FW, Ju Q, et al. New developments in our understanding of acne pathogenesis and treatment. Exp Dermatol. 2009;18:821-832.
2. Cunliffe WJ, Holland DB, Clark SM, et al. Comedogenesis: some aetiological, clinical and therapeutic strategies. Dermatology. 2003;206:11-16.
3. Bowe W, Kober M. Therapeutic update: acne. J Drugs Dermatol . 2014;13:235-238.
4. Jeremy AH, Holland DB, Roberts SG, et al. Inflammatory events are involved in acne lesion initiation. J Invest Dermatol . 2003;121:20-27.
5. Kim J, Ochoa MT, Krutzik SR, et al. Activation of toll-like receptor 2 in acne triggers inflammatory cytokine responses. J Immunol . 2002;169:1535-1541.
6. Kistowska M, Gehrke S, Jankovic D, et al. IL-1beta drives inflammatory responses to Propionibacterium acnes in vitro and in vivo. J Invest Dermatol. 2014;134:677-685.
7. Contassot E, French LE. New insights into acne pathogenesis: Propionibacterium acnes activates the inflammasome. J Invest Dermatol . 2014;134:310-313.
8. Vowels BR, Yang S, Leyden JJ. Induction of proinflammatory cytokines by a soluble factor of Propionibacterium acnes : implications for chronic inflammatory acne. Infect Immun . 1995;63:3158-3165.
9. Qin M, Pirouz A, Kim MH, et al. Propionibacterium acnes induces IL-1beta secretion via the NLRP3 inflammasome in human monocytes. J Invest Dermatol . 2014;134:381-388.
10. Li ZJ, Choi DK, Sohn KC, et al. Propionibacterium acnes activates the NLRP3 inflammasome in human sebocytes. J Invest Dermatol . 2014;134:2747-2756.
11. Selway JL, Kurczab T, Kealey T, et al. Toll-like receptor 2 activation and comedogenesis: implications for the pathogenesis of acne. BMC Dermatol. 2013;13:10.
12. Jugeau S, Tenaud I, Knol AC, et al. Induction of toll-like receptors by Propionibacterium acnes. Br J Dermatol . 2005;153:1105-1113.
13. XOMA announces encouraging interim results from gevokizumab phase 2 study for moderate to severe acne vulgaris [press release]. Berkley, CA: XOMA Corporation; January 7, 2013. http://www.servier.com/content/xoma-announces-encouraging-interim-results-gevokizumab-phase-2-study-moderate-severe-acne. Accessed November 5, 2014.
14. Leemans JC, Cassel SL, Sutterwala FS. Sensing damage by the NLRP3 inflammasome. Immunol Rev . 2011;243:152-162.
15. Dispenza MC, Wolpert EB, Gilliland KL, et al. Systemic isotretinoin therapy normalizes exaggerated TLR-2-mediated innate immune responses in acne patients. J Invest Dermatol. 2012;132:2198-2205.
16. Zuliani T, Khammari A, Chaussy H, et al. Ex vivo demonstration of a synergistic effect of adapalene and benzoyl peroxide on inflammatory acne lesions. Exp Dermatol . 2011;20:850-853.
